Cedars-Sinai Medical Center Hematology and Medical Oncology

Topics

• Renal cell carcinoma treatment 195
• Lung Cancer Treatments and Mutations 88
• Cancer Immunotherapy and Biomarkers 75
• Pancreatic and Hepatic Oncology Research 73
• Prostate Cancer Treatment and Research 63
• Hematopoietic Stem Cell Transplantation 51
• Cancer Genomics and Diagnostics 43
• Neuroendocrine Tumor Research Advances 43
• Immunotherapy and Immune Responses 36
• Acute Myeloid Leukemia Research 32
• CAR-T cell therapy research 26
• Chronic Myeloid Leukemia Treatments 25

Most cited

1. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.

   Nature medicine · 2025 · 207 citations · Yuan Yuan

2. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.

   Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 393 citations · Karen Reckamp

3. Ponsegromab for the Treatment of Cancer Cachexia.

   The New England journal of medicine · 2024 · 260 citations · Andrew Hendifar

4. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

   The Lancet. Oncology · 2021 · 510 citations · Andrew Hendifar

5. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 270 citations · Andrew Hendifar

6. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.